Introduction
============

It is a common phenomenon that the symptoms and signs are slightly different among patients with the same disease ([@b1-etm-0-0-7068]). For instance, coronary heart disease (CHD) manifests as chest pain ([@b2-etm-0-0-7068]). However, certain patients suffer from a stabbing pain, while others have complaints of a burning pain ([@b3-etm-0-0-7068]). Within the framework of Traditional Chinese Medicine (TCM) theory, practitioners always prescribe a medical formula based on symptoms and signs ([@b4-etm-0-0-7068]). In fact, TCM practitioners may divide patients with the same disease into several subtypes according to these slight differences and prescribe the corresponding formulae. In TCM theory, these subtypes are known as Zheng ([@b5-etm-0-0-7068]). It is renowned that the advancement of Zheng depends on the genes inherited from the parents, the lifestyle and the environmental conditions, which may differ between individual patients, and therefore, different types of Zheng exist ([@b6-etm-0-0-7068]). The first rule of Zheng is that one type of disease may be divided into several different Zheng ([@b7-etm-0-0-7068]).

A disequilibrium of the body\'s original condition is accountable for the development of Zheng, and certain deviations from the equilibrium may lead to certain types of disease and manifestations thereof ([@b8-etm-0-0-7068]). For instance, Qi stagnation and blood stasis syndrome (QSBSS), a type of Zheng, describes the condition of unsmooth flow of Qi and blood, which may occur in diseases including CHD, chronic gastritis (CG) and rheumatoid arthritis (RA) ([@b9-etm-0-0-7068]). This exemplifies the second rule of Zheng, namely that one type of Zheng may be the basis of several different types of disease ([@b7-etm-0-0-7068]). However, the western scientific basis for this theory, including the substantial essence of this Zheng, remains to be fully elucidated. Previous studies in the field mainly focus on the subtypes of one disease based on Zheng, while those on the biological basis of the same Zheng in different diseases are scarce ([@b10-etm-0-0-7068],[@b11-etm-0-0-7068]).

The genetic profile of an individual provides information on what could theoretically happen in the body, while protein expression profiles are representative of the processes that are active in the body at the time-point of determination ([@b12-etm-0-0-7068]). Of note, RNAs are the connection between DNAs and proteins, which reflect the interaction of the genotype and the environment ([@b8-etm-0-0-7068]). Among the different types of RNAs, messenger RNAs (mRNAs) are transcripts of DNA and the information they carry is transferred by their translation into proteins in accordance with the central dogma ([@b13-etm-0-0-7068]). Long non-coding RNAs (lncRNAs) are a class of non-protein-coding RNAs of \>200 nucleotides in length, and they are known to have roles in controlling chromatin structure, transcriptional regulation and post-transcriptional processing ([@b14-etm-0-0-7068],[@b15-etm-0-0-7068]). Furthermore, circular RNAs (circRNAs), which have drawn an increasing amount of attention recently, are a type of non-canonical form of alternative splicing and are more stable than linear RNAs ([@b16-etm-0-0-7068],[@b17-etm-0-0-7068]). Network pharmacology studies based on the theory of systems biology may be used for the preliminary validation of the interaction between TCM herbs and RNA targets ([@b18-etm-0-0-7068]). Due to its core methods based on the holistic view and the dynamic balance of the human body, network pharmacology is useful for the study of TCM herbs with complex mechanisms of action ([@b19-etm-0-0-7068]). In the present study, a network pharmacology analysis was employed to preliminarily validate the differentially expressed (DE) RNAs in subjects with QSBSS. The purpose of the present study was to explore the biological basis of one common Zheng, QSBSS, from the perspective of ncRNAs and mRNAs in a diversity of associated diseases.

Materials and methods
=====================

### Patients and samples

The protocol of the present study was approved by the Ethics Committee of Guang\'anmen Hospital (Beijing, China). The study included 5 patients with CHD and QSBSS (group a), 5 patients with CG and QSBSS (group b), 5 patients with RA and QSBSS (group c) and 5 completely healthy subjects (control) who presented at Guang\'anmen Hospital affiliated to the China Academy of Chinese Medical Sciences (Beijing, China) between October 2016 and December 2016. Informed consent was provided by all of the participants prior to the study.

The diagnosis of QSBSS was based on the judgement of an expert clinician according to the standard criteria approved by the China Food and Drug Administration ([@b20-etm-0-0-7068]) and the scaled diagnosis criteria, which is used to diagnose Qi Stagnation and Blood Stasis Syndrome ([@b21-etm-0-0-7068]). The criteria for QSBSS included primary symptoms and signs \[i) distending pain; ii) tingling sensation anywhere on the body; iii) pain in a fixed place; iv) pain aggravated by touch; v) lumps in the body; vi) self-reported irritability; vii) clinical depression diagnosed by a psychiatrist\], secondary symptoms and signs \[i) loss of appetite; ii) paleness of the face; iii) hemorrhagic spots on any part of the body\], TCM tongue presentations \[i) purple, dusky tongue; ii) stasis macules or stasis spots on the tongue\] and pulse presentation \[i) choppy pulse; ii) wiry pulse\] ([@b22-etm-0-0-7068]). A patient was diagnosed with QSBSS if they had \>2 of the primary symptoms and signs, \>1 of the secondary symptoms and signs, and 1 of the tongue or pulse presentations. The diagnosis of CHD, RA and CG were based on guidelines for the diagnosis and management of patients with stable ischaemic heart disease ([@b23-etm-0-0-7068]), the diagnosis and treatment for rheumatoid arthritis ([@b24-etm-0-0-7068]) and the consensus of chronic gastritis ([@b25-etm-0-0-7068]), respectively. From each of the patients, blood samples (3--4 ml) were collected in EDTA-containing tubes.

### RNA isolation and library preparation

RNA degradation and contamination was monitored on 1% agarose gels. RNA purity was confirmed using the Agencourt AMPure XP (cat. no. A63881; Beckman Coulter, Brea, CA, USA). RNA integrity was assessed using the RNA Nano 6000 Assay Kit for the Bioanalyzer 2100 system (cat. no. 5067-1511; Agilent Technologies, Inc., Santa Clara, CA, USA). The methods of lncRNA quantification were identical to the conventional methods for mRNAs. Quantification of circRNAs was performed with exonuclease to exclude non-circRNAs. After RNA extraction, the total RNA was digested with TruSeq Stranded Total RNA with Ribo-Zero Gold (cat. no. 15021048; Illumina, Inc., San Diego, CA, USA). The sample was then subjected to reverse transcription using SuperScript II Reverse Transcriptase (cat. no. 18064014; Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA).

A total of 3 µg RNA per sample was used as input material for the RNA sample preparations. First, ribosomal (r)RNA was removed using Agencourt RNAClean XP (cat. no. A63987; Beckman Coulter), and rRNA-free material was cleaned up by ethanol precipitation. Subsequently, sequencing libraries were generated using the rRNA-depleted RNA. Library preparation was performed according to manufacturer\'s protocol (Illumina). In brief, fragmentation was performed using divalent cations at 94°C in 5 µl rRNA Binding Buffer and 5 µl rRNA Removal Mix-Gold. First-strand complementary (c)DNA was synthesized using 8 µl First Strand Synthesis Act D Mix and SuperScript II Reverse Transcriptase. Second-strand cDNA synthesis was performed using 5 µl End Repair Control (2 µl End Repair Control + 98 µl Resuspension Buffer). The reaction buffer contained deoxynucleoside triphosphate where thymine was replaced by uracil. After adenylation of the 3′ends of the DNA fragments, an adaptor with a hairpin loop structure was ligated to prepare for hybridization. To select cDNA fragments of preferentially 150--200 bp in length, the library fragments were purified using the AMPure XP system (cat. no. A63881; Beckman Coulter). The DNA fragment was enriched by using 5 µl polymerase chain reaction (PCR) Primer Cocktail and 25 µl PCR Master Mix prior to performing PCR. The mixture was incubated in the following conditions: 98°C for 30 sec, 15 cycles 98°C for 10 sec, 60°C for 30 sec, 72°C for 30 sec, then 72°C for 5 min and held at 10°C. Finally, products were purified (AMPure XP system) and library quality was assessed on the Agilent Bioanalyzer 2100 system.

### Sequencing of RNAs and DE RNAs analysis

The clustering of the index-coded samples was performed on a cBot Cluster Generation System using TruSeq PE Cluster Kit v3cBot-HS (Illumina) according to the manufacturer\'s protocols. After cluster generation, the libraries were sequenced on an Illumina HiSeq 2,500 platform, and 125 bp paired-end and 50 bp single-end reads were generated. The number of reads for each sample was 8×10^7^. The number of clean bases of lncRNAs, circRNAs and mRNAs for each sample in filtered data was 12--13 Gb. The error rate of each base in lncRNAs, circRNAs and mRNAs for each sample was \<0.001. The spliced transcription products of each sample were combined and screened as lncRNAs with Cuffmerge program in the Cufflinks 2.2.1 software package. All transcripts that overlapped with known mRNAs, other non-coding RNA and non-lncRNA were discarded. Next, the transcripts that longer than 200 bp and \>2 exons were obtained, and CPC (version 0.9-r2) ([@b26-etm-0-0-7068]), PLEK (version 1.2) ([@b27-etm-0-0-7068]), CNCI (version 1.0) ([@b28-etm-0-0-7068]) and Pfam (version 30) ([@b29-etm-0-0-7068]) software packages were used to predict transcripts with coding potential. The characteristics (including length, type and number of exons) of lncRNA were analysed after screening by the Cuffcompare program in the Cufflinks 2.2.1 software package ([@b30-etm-0-0-7068]). CircRNAs were identified using the CircRNA Identifier tool ([@b31-etm-0-0-7068]). The expression of lncRNAs were calculated using fragments per kb per million reads (FPKM), while the expression of circRNAs were calculated by spliced reads per million reads (RPM). Then, DESeq2 with negative binomial distribution was used to analyse DE of RNAs ([@b32-etm-0-0-7068]). All sequencing processes and analyses were performed by Shanghai OE Biotech Co., Ltd. (Shanghai, China).

### Gene ontology (GO) annotations and Kyoto encyclopedia of genes and genomes (KEGG) pathway analysis

GO annotations and KEGG pathway analysis were performed to investigate the possible roles of the DE ncRNAs. GO annotations were performed to identify regulatory networks of DE genes (<http://geneontology.org>). KEGG analysis was also performed to explore the enriched pathways of the DE RNAs based on the KEGG database (<http://www.genome.jp/kegg/>). To reveal the role and interactions among the DE ncRNAs and mRNAs in QSBSS patients, an ncRNAs regulatory network was constructed using Cytoscape software version 3.2.1 (<http://www.cytoscape.org/>).

### Network pharmacology validation

The process of network pharmacology validation was performed in three steps. First, according to the sequencing results of DE RNAs, the RNA targets associated with QSBSS were prepared by ID normalization at <http://www.uniprot.org/> ([@b33-etm-0-0-7068]). Next, the active components of Xuefu Zhuyu decoction, a classic and CFDA-approved TCM formula for treating QSBSS, were retrieved from the TCM Systems Pharmacology Database (TCMSP) and the TCM Integrated Database ([@b34-etm-0-0-7068],[@b35-etm-0-0-7068]). The compounds were then screened according to parameters including drug-likeness (DL) and oral bioavailability (OB), and the specific ingredients were selected if their DL ≥0.18 and OB ≥30%, suggested criteria given by the TCMSP database ([@b34-etm-0-0-7068]). Finally, the targets of the compounds were predicted using the TCMSP analysis platform and the merged compound-RNA target network was constructed using Cytoscape (version 3.2.1), in order to determine whether any of the DE RNAs associated with QSBSS were targets of the components of Xuefu Zhuyu decoction.

### Statistical analysis

The data regarding the clinical characteristics of the participants are expressed as the mean ± standard error of the mean and the corresponding results were statistically analyzed using one-way analysis of variance. The results of DE RNAs were analyzed by the algorithm of DESeq2 in R software ([@b32-etm-0-0-7068]). The regulatory network for ncRNAs was analyzed by the algorithm of ClueGo in Cytoscape software. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Clinical characteristics of participants

A total of 20 participants were recruited for the present study and were divided into 4 groups. The clinical characteristics of these 4 groups were listed in [Table I](#tI-etm-0-0-7068){ref-type="table"}. The 4 groups were matched in terms of sex, as well as body height and weight, and there were no significant differences in terms of the frequency of hypertension, diabetes mellitus and cancer between the groups (P\>0.05).

### DE ncRNAs and mRNAs, and their overlap among patient groups with different types of disease

The results of the DE ncRNAs and mRNAs in the comparisons were as follows: A total of 678 DE lncRNAs (448 upregulated and 230 downregulated), 166 DE circRNAs (59 upregulated and 107 downregulated), and 2,676 DE mRNAs (1,287 upregulated and 1,389 downregulated) were identified in group a (CHD with QSBSS vs. controls), respectively. In group b (CG with QSBSS vs. control), 1,158 DE lncRNAs (901 upregulated and 257 downregulated), 116 DE circRNAs (38 upregulated and 78 downregulated) and 2,880 DE mRNAs (1,336 upregulated and 1,544 downregulated) were detected. A total of 697 DE lncRNAs (470 upregulated and 227 downregulated), 120 DE circRNAs (49 upregulated and 71 downregulated) and 2,776 DE mRNAs (1,420 upregulated and 1,356 downregulated) were identified in group c (RA with QSBSS vs. control). DE ncRNAs ([Figs. 1](#f1-etm-0-0-7068){ref-type="fig"} and [2](#f2-etm-0-0-7068){ref-type="fig"}) and mRNAs ([Fig. 3](#f3-etm-0-0-7068){ref-type="fig"}) in the samples were displayed using Volcano plot and clustering maps for groups a, b and c individually. The top 10 upregulated and top 10 downregulated lncRNAs, circRNAs and mRNAs in groups a, b and c are listed in [Tables II](#tII-etm-0-0-7068){ref-type="table"}, [III](#tIII-etm-0-0-7068){ref-type="table"} and [IV](#tIV-etm-0-0-7068){ref-type="table"}, respectively. Overlapped DE lncRNAs, circRNAs and mRNAs among groups a, b and c were illustrated in a Venn diagram ([Fig. 4](#f4-etm-0-0-7068){ref-type="fig"}). A total of 374 up-regulated DE mRNAs, 323 down-regulated DE mRNAs, 81 up-regulated DE lncRNAs, 23 down-regulated DE lncRNAs and 2 down-regulated DE circRNAs overlapped. No up-regulated DE circRNAs overlapped.

### Functional prediction of ncRNAs

To further determine the possible functions of the overlapped DE RNAs and investigate the association between the functional groups and their underlying mechanisms in the biological networks, the Cytoscape plugin ClueGo was utilized. Significant GO terms in the categories MF and BP were specifically associated with nucleic acid metabolic process, regulation of macromolecule metabolic process, peptidyl-lysine modification and mitotic cell cycle ([Figs. 5](#f5-etm-0-0-7068){ref-type="fig"} and [6](#f6-etm-0-0-7068){ref-type="fig"}). Of note, these DE RNAs coordinate with each other to perform their functions and the relevant major biochemical pathways and signal transduction pathways were predicted by enrichment analysis based on the KEGG database. A scatterplot of the DE RNAs was employed to demonstrate the KEGG enrichment analysis. In this plot, the degree of KEGG enrichment is assessed by the enrichment factor, P-value and number of genes. A greater enrichment factor is associated with a P-value closer to zero and a greater number of genes, and therefore a more significantly enriched pathway. When the data were analyzed regarding the co-expression of genes of DE lncRNAs, DE mRNAs and target genes of DE circRNAs, the most significantly enriched KEGG pathways were sphingolipid, neurotrophin, AMP-activated protein kinase (AMPK), mRNA surveillance pathway and endocytosis ([Fig. 7](#f7-etm-0-0-7068){ref-type="fig"}). These major BPs and signal transduction pathways provide insight regarding further directions of research on the biological basis of QSBSS.

### Merged network of DE RNAs and target fishing

As presented in the network for compounds and targets ([Fig. 8](#f8-etm-0-0-7068){ref-type="fig"}) and the merged network ([Fig. 9](#f9-etm-0-0-7068){ref-type="fig"}), the targets of active components of Xuefu Zhuyu decoction partly covered the targets in the DE RNAs of QSBSS discovered by sequencing. The shared targets of QSBSS and Xuefu Zhuyu Decoction were interleukin 1β, DNA topoisomerase I, potassium voltage-gated channel subfamily H member 2, nuclear receptor coactivator 1, mitogen-activated protein kinase 8, insulin-like growth factor 1 receptor and calcium/calmodulin-dependent protein kinase kinase 2.

Discussion
==========

In the present study, expression profiles of lncRNAs, circRNAs and mRNA were obtained by next-generation sequencing and compared in patients with QSBSS and three different types of disease (CHD, CG or RA vs. normal controls). A total of 104 lncRNAs, 2 circRNAs and 697 mRNAs were finally identified to be significantly DE among groups a, b and c in a Venn diagram. These DE RNAs were subsequently displayed in a Volcano Plot and integrated into hierarchical categories according to heat maps and hierarchical clustering. GO and KEGG analyses were used to predict their relevant functions by ClueGo. A network pharmacology study was also performed to preliminarily confirm the DE RNAs with the hypothesis that the DE RNAs of QSBSS may be regulated by the TCM herbs with efficacy in treating QSBSS. These DE RNAs and their corresponding pathways may be considered highly relevant to QSBSS, and may contribute to the explanation of Zheng and prediction of therapeutic targets of the TCM formula.

QSBSS is a common Zheng that is thought to be associated with the manifestation of numerous types of disease, including CHD, CG and RA, and it is always used to define the condition of unsmooth flow of Qi and blood ([@b36-etm-0-0-7068]). In addition to distending pain in a fixed place, one symptom of QSBSS is emotional problems, including irritability and depression ([@b21-etm-0-0-7068]). The development of QSBSS is complex ([@b37-etm-0-0-7068]) and the mechanism remains largely elusive. The competing endogenous (ce)RNA hypothesis posits that miRNA may bind to an argonaute protein and form the miRNA-guided RNA-induced silencing complex (RISC) to target the relevant mRNA, leading to accelerated degradation, blocked translation and decreased expression, while ceRNA with shared target sites competes for miRNA targeting and binding in the RISC, thus sequestering the miRNA activity, resulting in repression of the expression the target gene of the respective miRNA ([@b14-etm-0-0-7068]). Furthermore, lncRNA, circRNA and pseudogene transcripts have gained considerable attention as they may work together to regulate ceRNA mechanisms. Despite the growing interest in exploring the biological basis of Zheng from DNA and RNA ([@b38-etm-0-0-7068]--[@b41-etm-0-0-7068]), the molecular mechanisms underlying the interaction of ncRNAs and mRNAs in QSBSS have remained largely elusive. Therefore, for the first time, the present study provided and compared expression profiles of lncRNAs, circRNAs and mRNAs in QSBSS obtained by next-generation sequencing. These pioneering discoveries may deepen the current understanding of the mechanisms of Zheng as well as provide a foundation for further scientific research into the molecular basis of TCM theory.

Previous studies have indicated the links between QSBSS and the processes of inflammation, immune response and sympathetic regulation ([@b42-etm-0-0-7068]--[@b44-etm-0-0-7068]). Of note, glycoprotein containing disulfide bonds, G protein-coupled receptor signaling pathways and catecholamine neurotransmitter activity were identified to constitute the biological basis of QSBSS through methods of data mining, which integrated the results of nearly all of the previous research on QSBSS ([@b45-etm-0-0-7068]). Another previous study suggested that QSBSS patients suffered from an imbalance of lower pneumogastric nerve activity and higher sympathetic nerve activity, as indicated by a heart rate variability analysis ([@b43-etm-0-0-7068]). Although evidence for the biological basis of QSBSS has accumulated, no comprehensive analysis of the ncRNA and mRNA profile in QSBSS has been performed to date, to the best of our knowledge. Thus, next-generation sequencing was applied in the present study to analyze DE ncRNAs and mRNAs in patients with QSBSS.

Bioinformatics analysis of the RNA sequencing results of the present study indicated that DE RNAs in QSBSS were most significantly enriched in pathways including the sphingolipid signaling pathway, the neurotrophin signaling pathway, AMPK and endocytosis. These results imply that QSBSS is not only associated with an imbalance of neural function, but also with a deregulation of energy metabolism. Specifically, sphingomyelin and its metabolic products are known to have second messenger functions in a variety of cellular signaling pathways ([@b46-etm-0-0-7068],[@b47-etm-0-0-7068]). Among its metabolic products, ceramide and S1P regulate cellular responses to stress, with generally opposing effects ([@b48-etm-0-0-7068],[@b49-etm-0-0-7068]). Neurotrophins are a family of trophic factors involved in the differentiation and survival of neural cells, which are central for the development of diseases including hereditary sensory and autonomic neuropathy, as well as congenital pain insensitivity with anhidrosis ([@b50-etm-0-0-7068]). Endocytosis is a mechanism for cells to remove ligands, nutrients, plasma membrane proteins and lipids from the cell surface, which is essential for the advance of hereditary sensory and autonomic neuropathy ([@b51-etm-0-0-7068]). AMPK is a serine threonine kinase that is highly conserved through evolution and the AMPK system acts as a sensor of the cellular energy status ([@b52-etm-0-0-7068],[@b53-etm-0-0-7068]). These functions of enriched pathways may be indicative of why QSBSS frequently manifests as pain accompanied with obscure sensations, including a distending and tingling sensation, as well as emotional problems, including irritability and depression ([@b17-etm-0-0-7068]). Of note, QSBSS is a stagnation of Qi and the flow of blood, which is known to carry the substance, including oxygen and energy in the body ([@b54-etm-0-0-7068]). Hence, it is likely that the biological basis of QSBSS may be directly associated with a dysfunction of energy metabolism and the autonomic nervous system, which requires more in-depth study in the future.

To the best of our knowledge, the present study was the first to explore the biological basis of Zheng in subjects with different diseases rather than different Zheng in one disease and it was attempted to interpret QSBSS, one of the common Zheng, from the perspective of ncRNAs and mRNAs, which were determined by next-generation sequencing technology. It is worth mentioning that the grouping design in the present study may be implemented to assess any type of Zheng in further studies. However, one of the limitations of the present study is the lack of validation of DE RNAs by quantitative (q)PCR as the cohort size was very small and qPCR analysis was not performed, which is likely to be resolved in a future study. Besides, the inter-group and inter-patient variability should also be analysed in the future study. Furthermore, one intended utility of these DE RNAs and enriched pathways is to predict the potential targets of TCM formulae that treating QSBSS, which mainly include interleukin 1β, DNA topoisomerase I and potassium voltage-gated channel subfamily H member 2. These putative targets may be candidates for experimental validation of the mechanisms of action of the TCM formulae, which may be essential for the optimization of ancient formulae and the discovery of novel drugs.
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![Volcano plot and clustering map of DE lncRNAs. Upper panel, volcano plots indicating up- and down-regulated lncRNAs for the comparison of the normal controls with groups (A) a, (B) b and (C) c. The respective heat maps presenting the hierarchical clustering of DE lncRNAs are displayed in the lower panel. Groups: a, QSBSS patients with coronary heart disease (n=5); b, QSBSS patients with chronic gastritis (n=5); c, QSBSS patients with rheumatoid arthritis (n=5). QSBSS, Qi stagnation and blood stasis syndrome; lncRNA, long non-coding RNA; DE, differentially expressed.](etm-17-02-1206-g00){#f1-etm-0-0-7068}

![Volcano plot and clustering map of DE circRNAs. Upper panel, volcano plots indicating up- and down-regulated circRNAs for the comparison of the normal controls with groups (A) a, (B) b and (C) c. The respective heat maps presenting the hierarchical clustering of DE circRNAs are displayed in the lower panel. Groups: a, QSBSS patients with coronary heart disease (n=5); b, QSBSS patients with chronic gastritis (n=5); c, QSBSS patients with rheumatoid arthritis (n=5). QSBSS, Qi stagnation and blood stasis syndrome; circRNA, circular RNA; DE, differentially expressed.](etm-17-02-1206-g01){#f2-etm-0-0-7068}

![Volcano plot and clustering map of DE mRNAs. Upper panel, volcano plots indicating up- and down-regulated mRNAs for the comparison of the normal controls with groups (A) a, (B) b and (C) c. The respective heat maps presenting the hierarchical clustering of DE mRNAs are displayed in the lower panel. Groups: a, QSBSS patients with coronary heart disease (n=5); b, QSBSS patients with chronic gastritis (n=5); c, QSBSS patients with rheumatoid arthritis (n=5). QSBSS, Qi stagnation and blood stasis syndrome; DE, differentially expressed.](etm-17-02-1206-g02){#f3-etm-0-0-7068}

![Venn diagram of overlapped DE lncRNAs, circRNAs and mRNAs. Venn diagrams displaying the number of overlapped up-regulated (upper panel) and down-regulated (lower panel) DE (A) lncRNAs, (B) circRNAs and (C) mRNAs among groups a, b and c. Groups: (a) QSBSS patients with coronary heart disease (n=5); (b) QSBSS patients with chronic gastritis (n=5); (c) QSBSS patients with rheumatoid arthritis (n=5). QSBSS, Qi stagnation and blood stasis syndrome; lncRNA, long non-coding RNA; circRNA, circular RNA; DE, differentially expressed.](etm-17-02-1206-g03){#f4-etm-0-0-7068}

![Analysis of DE RNAs by ClueGo. The enrichment analysis of DE RNAs was performed using ClueGo and the most significant terms are presented, where a higher score indicates a higher number of genes involved. The same color indicates that it was possible to cluster the respective terms. DE, differentially expressed.](etm-17-02-1206-g04){#f5-etm-0-0-7068}

![GO analysis of DE RNAs. The GO enrichment analysis of DE RNAs is represented by the pie charts. GO, gene ontology; DE, differentially expressed.](etm-17-02-1206-g05){#f6-etm-0-0-7068}

![Enriched Kyoto Encyclopedia of Genes and Genomes pathways. The pathway scatterplot displays the statistics of the pathway enrichment of the differentially expressed RNAs. MAPK, mitogen-activated protein kinase; NF, nuclear factor; Fox, forkhead box; AMPK, 5′AMP-activated protein kinase; NOD, nucleotide-binding oligomerization domain.](etm-17-02-1206-g06){#f7-etm-0-0-7068}

![Putative targets for Xuefu Zhuyu decoction, a treatment for Qi stagnation and blood stasis syndrome. The triangular nodes represent the screened ingredients and the circular nodes represent the predicted targets.](etm-17-02-1206-g07){#f8-etm-0-0-7068}

![Network of the targets of Xuefu Zhuyu decoction (treatment for QSBSS) and differentially expressed RNAs in QSBSS. The green triangular nodes represent active components, the green circular nodes represent targets and the red nodes represent shared targets of QSBSS and Xuefu Zhuyu Decoction. QSBSS, Qi stagnation and blood stasis syndrome.](etm-17-02-1206-g08){#f9-etm-0-0-7068}

###### 

Clinical characteristics of sequencing subjects.

  Characteristic      Control (n=5)   Group a (n=5)   Group b (n=5)   Group c (n=5)   P-value
  ------------------- --------------- --------------- --------------- --------------- ---------
  Males               3               3               3               1               0.051
  Age (years)         50.40±7.26      63.60±5.12      64.40±6.38      58.60±5.94      0.010
  Height (cm)         163.00±9.89     162.40±8.01     169.20±5.80     165.80±5.35     0.482
  Weight (kg)         66.60±11.28     70.30±9.91      75.80±12.37     60.60±11.26     0.225
  Hypertension        0               2               1               1               0.337
  Diabetes mellitus   0               0               2               1               0.058
  Cancer              0               0               1               0               0.059

Values are expressed as the mean ± standard error of the mean or n. Groups: a, QSBSS patients with coronary heart disease (n=5); b, QSBSS patients with chronic gastritis (n=5); c, QSBSS patients with rheumatoid arthritis (n=5). QSBSS, Qi stagnation and blood stasis syndrome.

###### 

Detailed information of the top 10 upregulated and 10 downregulated lncRNAs.

  A, Group a                                                                                                    
  --------------------- --------------- ---------------- -------------- ------------------------ -------------- ----------------
  lnc-SUPT16H-3:1       Novel_lncRNA    28.45432035      374.5259054    3.718345886              2.06×10^−8^    Up
  lnc-RALGAPA1-4:1      Novel_lncRNA    76.75550691      359.25044      2.226647757              8.13×10^−7^    Up
  LINC01619:1           Novel_lncRNA    44.81014998      196.9603127    2.136007497              1.03×10^−5^    Up
  lnc-PTP4A2-3:4        Novel_lncRNA    7.397430792      297.6452117    5.330425581              2.06×10^−5^    Up
  lnc-PKDCC-4:1         Novel_lncRNA    13.12539052      94.73577234    2.851548944              2.76×10^−5^    Up
  lnc-SOX4-2:1          Novel_lncRNA    0.187964496      45.41608604    7.916599391              4.77×10^−5^    Up
  LINC-PINT:20          Novel_lncRNA    0.68761825       37.12070593    5.7544725                6.62×10^−5^    Up
  lnc-FAN1-6:1          Novel_lncRNA    3.007431931      76.98804768    4.678030497              1.25×10^−4^    Up
  lnc-NEDD9-2:3         Novel_lncRNA    204.8829122      607.9154915    1.569071119              1.40×10^−4^    Up
  lnc-UACA-6:3          Novel_lncRNA    2.85167033       53.72383561    4.235683197              2.03×10^−4^    Up
  lnc-CFLAR-1:1         Novel_lncRNA    317.5740647      42.23690812    −2.910516963             8.76×10^−10^   Down
  lnc-C18orf54-3:1      Novel_lncRNA    17.59737855      0.229176766    −6.262755929             2.35×10^−5^    Down
  lnc-PTPN6-1:2         Novel_lncRNA    73.0536666       12.89197843    −2.502483005             2.46×10^−5^    Down
  lnc-TOB1-4:1          Novel_lncRNA    49.503338        5.280343401    −3.228822147             4.21×10^−5^    Down
  lnc-NINJ2-4:3         Novel_lncRNA    15.78127325      0.229176766    −6.105609007             7.60×10^−5^    Down
  lnc-VSTM5-1:12        Novel_lncRNA    88.5702391       19.58027393    −2.177421065             1.42×10^−4^    Down
  lnc-AC092329.1--1:5   Novel_lncRNA    20.45877718      0.948506969    −4.430917734             1.61×10^−4^    Down
  lnc-MDM1-1:10         Novel_lncRNA    54.70206769      9.823915046    −2.477225377             1.65×10^−4^    Down
  lnc-CRYBA4-1:53       Novel_lncRNA    121.6228189      28.76734593    −2.079909903             2.02×10^−4^    Down
  lnc-PTP4A2-3:3        Novel_lncRNA    244.8594302      0.916707064    −8.061277253             2.65×10^−4^    Down
                                                                                                                
  **B, Group b**                                                                                                
                                                                                                                
  **Gene ID**           **Gene name**   **BM_control**   **BM_QSBSS**   **log2 (fold change)**   **P-value**    **Regulation**
                                                                                                                
  LINC-PINT:20          Novel_lncRNA    0.669136799      34.68062215    5.695684784              7.29×10^−7^    Up
  lnc-FGL2-3:1          Novel_lncRNA    2.497604805      1065.79556     8.737169794              1.34×10^−5^    Up
  lnc-KIAA0748-2:1      Novel_lncRNA    38.88426047      178.264157     2.196758448              2.32×10^−5^    Up
  lnc-RCAN1-4:1         Novel_lncRNA    0.363197716      24.31360581    6.064864925              3.43×10^−5^    Up
  lnc-RTEL1.1--3:5      Novel_lncRNA    4.653772495      40.51149143    3.121858609              5.39×10^−5^    Up
  lnc-INSL4-5:1         Novel_lncRNA    19.05513281      95.23213668    2.321268839              6.94×10^−5^    Up
  lnc-PKDCC-4:1         Novel_lncRNA    12.72486822      76.09097524    2.580074638              7.43×10^−5^    Up
  lnc-RIMS3-5:1         Novel_lncRNA    29.60597764      126.9453778    2.100247466              8.52×10^−5^    Up
  lnc-LYRM7-4:1         Novel_lncRNA    36.08770968      151.2244038    2.067111483              8.82×10^−5^    Up
  lnc-CTNNA3-3:1        Novel_lncRNA    32.24888452      139.4355372    2.112277136              1.02×10^−4^    Up
  lnc-CFLAR-1:1         Novel_lncRNA    307.456305       0.353369173    −9.764989488             0.00×10^−11^   Down
  lnc-APEX1-3:1         Novel_lncRNA    211.245845       11.0242814     −4.26016644              2.00×10^−13^   Down
  lnc-PRKAR1A-2:1       Novel_lncRNA    1122.360252      283.5025529    −1.985102191             2.10×10^−6^    Down
  lnc-RAG1-5:3          Novel_lncRNA    51.27926169      4.964879496    −3.368544883             4.78×10^−6^    Down
  LINC00936:1           Novel_lncRNA    963.0937225      258.3817153    −1.89817222              2.11×10^−5^    Down
  lnc-ZNF101-3:1        Novel_lncRNA    108.7867263      14.13476693    −2.944182536             2.60×10^−5^    Down
  lnc-MB21D1-3:5        Novel_lncRNA    6778.947852      1925.503917    −1.815825315             4.63×10^−5^    Down
  lnc-CCDC111-2:1       Novel_lncRNA    87.39175981      12.76026571    −2.775838883             9.09×10^−5^    Down
  lnc-UGDH-3:2          Novel_lncRNA    132.0477892      28.57958569    −2.20800324              1.00×10^−4^    Down
  lnc-TOB1-4:1          Novel_lncRNA    47.99402748      5.477222185    −3.131338574             1.43×10^−4^    Down
                                                                                                                
  **C, Group c**                                                                                                
                                                                                                                
  **Gene ID**           **Gene name**   **BM_control**   **BM_QSBSS**   **log2 (fold change)**   **P-value**    **Regulation**
                                                                                                                
  lnc-SUPT16H-3:1       Novel_lncRNA    28.98663335      473.8065463    4.030838445              6.38×10^−8^    Up
  lnc-PTP4A2-3:4        Novel_lncRNA    7.51850112       290.4813765    5.271856785              1.90×10^−7^    Up
  PAX8-AS1:6            Novel_lncRNA    28.16175293      142.8994525    2.343191347              6.99×10^−5^    Up
  lnc-ACTR1B-3:18       Novel_lncRNA    0.522432354      17.71173166    5.083317214              1.36×10^−4^    Up
  lnc-OR4F21-1:1        Novel_lncRNA    3.529033861      34.29076606    3.280474957              1.37×10^−4^    Up
  lnc-ANAPC7-3:1        Novel_lncRNA    0.511499328      17.62430933    5.106690566              1.47×10^−4^    Up
  SNHG4:19              Novel_lncRNA    5.177511537      36.41675096    2.814271445              3.52×10^−4^    Up
  lnc-HACL1-10:1        Novel_lncRNA    0.955682697      18.22549975    4.253282866              3.67×10^−4^    Up
  lnc-LYRM7-4:1         Novel_lncRNA    37.9577107       131.007337     1.787182722              4.35×10^−4^    Up
  lnc-UGT3A2-3:1        Novel_lncRNA    1.126190273      68.64681004    5.92967018               5.95×10^−4^    Up
  TCONS_00066371        XLOC_034909     206.0849162      0.190001322    −10.08301374             1.00×10^−13^   Down
  TCONS_00133003        XLOC_069024     168.4915946      24.48540625    −2.782682585             9.50×10^−8^    Down
  lnc-APEX1-3:1         Novel_lncRNA    221.6790465      35.26124522    −2.652317082             2.66×10^−6^    Down
  lnc-GPR123-2:1        Novel_lncRNA    145.0012968      27.90207696    −2.377621381             5.64×10^−6^    Down
  lnc-PTPN6-1:2         Novel_lncRNA    74.19783961      15.26041243    −2.281583228             1.19×10^−4^    Down
  lnc-MBP-2:6           Novel_lncRNA    16.34600311      0.412915251    −5.306948399             1.74×10^−4^    Down
  TCONS_00055344        XLOC_028836     57.55245189      10.47564043    −2.457838946             1.91×10^−4^    Down
  TCONS_00015300        XLOC_007246     68.91323715      14.48951949    −2.249771377             2.09×10^−4^    Down
  lnc-SPG7-1:6          Novel_lncRNA    20.96867059      1.140007934    −4.201119628             2.34×10^−4^    Down
  TCONS_00113555        XLOC_059030     13.52330416      0.199388024    −6.083725124             2.93×10^−4^    Down

Comparison A (Group a vs. Group control), B (Group b vs. Group control) and C (Group c vs. Group control). Groups: a, QSBSS patients with coronary heart disease (n=5); b, QSBSS patients with chronic gastritis (n=5); c, QSBSS patients with rheumatoid arthritis (n=5). lncRNA, long non-coding RNA; QSBSS, Qi stagnation and blood stasis syndrome; BM, base mean.

###### 

Detailed information of the top 10 upregulated and 10 downregulated circRNAs.

  A, Group a                                                                                                                                                      
  ---------------------------------------------------- --------------- ------------------- ---------------- -------------- ------------------------ ------------- ----------------
  circRNA_17075\|NC_000011.10:43830976_43840064\_+     HSD17B12        Sense-overlapping   1.32462559       7.971212934    2.589214633              1.31×10^−4^   Up
  circRNA_11571\|NC_000007.14:6046071_6050045\_-       EIF2AK1         Sense-overlapping   0.37603418       4.548890914    3.596579135              1.12×10^−3^   Up
  circRNA_26415\|NC_000020.11:37061103_37062270\_-     RBL1            Sense-overlapping   0.87921177       5.411278881    2.621686986              1.81×10^−3^   Up
  circRNA_18831\|NC_000012.12:94169153_94186473\_+     PLXNC1          Sense-overlapping   127.149245       180.8054391    0.507915189              2.85×10^−3^   Up
  circRNA_08586\|NC_000004.12:177353308_177353728\_+   NEIL3           Exonic              80.5534029       134.3022057    0.737465559              3.36×10^−3^   Up
  circRNA_07354\|NC_000004.12:15625252_15644708\_-     FBXL5           Sense-overlapping   5.48874207       13.87619515    1.338064586              3.74×10^−3^   Up
  circRNA_00060\|NC_000001.11:2302978_2304585\_+       SKI             Sense-overlapping   0.67309          4.659019059    2.791154914              3.88×10^−3^   Up
  circRNA_26127\|NC_000020.11:3963875_3974400\_-       RNF24           Sense-overlapping   7.43905456       15.06876907    1.018370387              5.88×10^−3^   Up
  circRNA_23305\|NC_000016.10:84979189_84981994\_-     ZDHHC7          Sense-overlapping   2.64881177       7.528229138    1.506965212              9.52×10^−3^   Up
  circRNA_07469\|NC_000004.12:38790070_38791231\_-     Novel_circRNA   Exonic              17.4723667       28.21041441    0.691152823              9.78×10^−3^   Up
  circRNA_11447\|NC_000006.12:158583954_158589782\_+   TMEM181         Sense-overlapping   36.7072718       15.15471652    −1.276299027             4.15×10^−5^   Down
  circRNA_08702\|NC_000005.10:34179013_34182867\_-     Novel_circRNA   Intergenic          8.27722775       1.722922054    −2.264290219             3.43×10^−4^   Down
  circRNA_05856\|NC_000003.12:51541498_51552063\_+     RAD54L2         Sense-overlapping   57.6149601       30.5210945     −0.916636766             9.97×10^−4^   Down
  circRNA_26641\|NC_000020.11:56381433_56384324\_-     AURKA           Sense-overlapping   13.2686213       5.198360651    −1.351889836             1.58×10^−3^   Down
  circRNA_09849\|NC_000005.10:155854549_155870424\_+   Novel_circRNA   Intergenic          10.8990358       4.058654063    −1.425127223             3.14×10^−3^   Down
  circRNA_14375\|NC_000009.12:33960826_33963791\_-     UBAP2           Sense-overlapping   10.1539178       2.658377854    −1.933418403             3.77×10^−3^   Down
  circRNA_05293\|NC_000003.12:3167634_3175269\_-       CRBN            Sense-overlapping   6.28998378       1.166948766    −2.430315076             3.93×10^−3^   Down
  circRNA_18046\|NC_000012.12:10386903_10393867\_-     KLRC4-KLRK1     Sense-overlapping   24.8329163       11.97296213    −1.052473572             4.43×10^−3^   Down
  circRNA_17571\|NC_000011.10:86250296_86256512\_+     EED             Sense-overlapping   4.04730028       0.383577527    −3.399369787             5.26×10^−3^   Down
  circRNA_17157\|NC_000011.10:57491224_57491862\_-     SLC43A1         Sense-overlapping   4.85469127       0.862811798    −2.492261744             5.42×10^−3^   Down
                                                                                                                                                                  
  **B, Group b**                                                                                                                                                  
                                                                                                                                                                  
  **Gene ID**                                          **Gene name**   **Type**            **BM_control**   **BM_QSBSS**   **log2 (fold change)**   **P-value**   **Regulation**
                                                                                                                                                                  
  circRNA_21868\|NC_000015.10:63213989_63214386\_+     RAB8B           Intronic            0.34767227       4.947228119    3.830820527              2.62×10^−3^   Up
  circRNA_05307\|NC_000003.12:5170503_5174414\_+       ARL8B           Sense-overlapping   0.69534454       5.271795149    2.922494414              2.74×10^−3^   Up
  circRNA_11390\|NC_000006.12:154212770_154223243\_-   IPCEF1          Sense-overlapping   4.98927089       13.78793369    1.466505359              3.04×10^−3^   Up
  circRNA_00019\|NC_000001.11:1669664_1734835\_-       SLC35E2B        Sense-overlapping   1.0430168        8.760815597    3.070302787              3.25×10^−3^   Up
  circRNA_07459\|NC_000004.12:38035588_38054338\_+     TBC1D1          Sense-overlapping   0.45711334       4.093290549    3.162637257              3.36×10^−3^   Up
  circRNA_17230\|NC_000011.10:65430769_65437657\_+     Novel_circRNA   Intergenic          5.53385736       13.02586425    1.235021733              5.65×10^−3^   Up
  circRNA_07354\|NC_000004.12:15625252_15644708\_-     FBXL5           Sense-overlapping   5.05562864       14.20073669    1.490003375              5.95×10^−3^   Up
  circRNA_06938\|NC_000003.12:182961226_182965753\_-   DCUN1D1         Sense-overlapping   1.48698271       5.932368937    1.996220447              8.90×10^−3^   Up
  circRNA_26020\|NC_000019.10:52588532_52592228\_+     Novel_circRNA   Intergenic          2.46658164       8.047647043    1.706053993              9.01×10^−3^   Up
  circRNA_17075\|NC_000011.10:43830976_43840064\_+     HSD17B12        Sense-overlapping   1.23520758       5.672992987    2.199356575              1.10×10^−2^   Up
  circRNA_23131\|NC_000016.10:68190768_68191775\_+     NFATC3          Exonic              8.7889668        1.963322605    −2.162396327             9.56×10^−4^   Down
  circRNA_10301\|NC_000006.12:24416397_24418578\_+     MRS2            Sense-overlapping   6.05013791       0.901748722    −2.746170651             1.88×10^−3^   Down
  circRNA_11368\|NC_000006.12:152329730_152331890\_-   SYNE1           Exonic              4.73930706       0.565708258    −3.066545998             2.89×10^−3^   Down
  circRNA_26904\|NC_000021.9:39218152_39218660\_-      BRWD1           Sense-overlapping   4.60809631       0.565708258    −3.026040733             3.20×10^−3^   Down
  circRNA_15770\|NC_000010.11:31908172_31910563\_-     ARHGAP12        Sense-overlapping   38.5982122       20.88132193    −0.88632098              4.47×10^−3^   Down
  circRNA_20028\|NC_000013.11:95161189_95170628\_-     ABCC4           Sense-overlapping   4.31735406       0.568986286    −2.923681624             4.66×10^−3^   Down
  circRNA_26634\|NC_000020.11:51516784_51524110\_-     NFATC2          Sense-overlapping   8.9643749        2.800608967    −1.678462422             6.29×10^−3^   Down
  circRNA_03181\|NC_000002.12:32377588_32395593\_+     BIRC6           Sense-overlapping   4.23291619       0.332762435    −3.669087438             6.94×10^−3^   Down
  circRNA_12096\|NC_000007.14:72830692_72831798\_+     Novel_circRNA   Intergenic          7.00764767       1.755228151    −1.997271671             8.52×10^−3^   Down
  circRNA_06618\|NC_000003.12:143985543_143989837\_+   C3orf58         Sense-overlapping   4.51771847       0.699135631    −2.691950103             8.72×10^−3^   Down
                                                                                                                                                                  
  **C, Group c**                                                                                                                                                  
                                                                                                                                                                  
  **Gene ID**                                          **Gene name**   **Type**            **BM_control**   **BM_QSBSS**   **log2 (fold change)**   **P-value**   **Regulation**
                                                                                                                                                                  
  circRNA_15618\|NC_000010.11:24629996_24635103\_-     ARHGAP21        Sense-overlapping   1.88682423       9.46047819     2.325953078              1.86×10^−4^   Up
  circRNA_12051\|NC_000007.14:66286511_66286709\_+     TPST1           Exonic              3.05288673       10.0082037     1.712937089              3.04×10^−4^   Up
  circRNA_09327\|NC_000005.10:95755396_95763620\_+     RHOBTB3         Sense-overlapping   25.9992577       45.80635744    0.817077408              1.10×10^−3^   Up
  circRNA_12851\|NC_000007.14:152263016_152315338\_-   KMT2C           Sense-overlapping   1.78037988       7.382084284    2.051843109              1.26×10^−3^   Up
  circRNA_22782\|NC_000016.10:23988508_24035547\_+     PRKCB           Sense-overlapping   6.91237695       15.18024088    1.134940885              3.68×10^−3^   Up
  circRNA_25741\|NC_000019.10:21987216_21988909\_-     ZNF208          Sense-overlapping   0.67237467       4.30048113     2.677160804              5.51×10^−3^   Up
  circRNA_03640\|NC_000002.12:61498673_61499894\_-     XPO1            Sense-overlapping   1.16372918       5.641809329    2.277402555              8.49×10^−3^   Up
  circRNA_07695\|NC_000004.12:55893552_55899884\_+     EXOC1           Sense-overlapping   0.35072822       2.994007933    3.093652605              9.37×10^−3^   Up
  circRNA_03222\|NC_000002.12:32633876_32640410\_+     TTC27           Sense-overlapping   2.93624913       8.323607273    1.503234514              1.08×10^−2^   Up
  circRNA_21325\|NC_000015.10:34860042_34867609\_-     AQR             Sense-overlapping   1.16372918       4.197502539    1.850775843              1.25×10^−2^   Up
  circRNA_18044\|NC_000012.12:10386903_10390027\_-     KLRK1           Sense-overlapping   9.31112428       1.861257049    −2.322678066             2.62×10^−4^   Down
  circRNA_18046\|NC_000012.12:10386903_10393867\_-     KLRC4-KLRK1     Sense-overlapping   23.1502828       9.766171882    −1.245164743             2.75×10^−4^   Down
  circRNA_17950\|NC_000012.12:350621_356537\_-         KDM5A           Sense-overlapping   5.35061004       0.47990746     −3.478875243             5.00×10^−4^   Down
  circRNA_01807\|NC_000001.11:155767425_155773210\_-   GON4L           Sense-overlapping   7.78597137       1.731447168    −2.168898673             1.16×10^−3^   Down
  circRNA_05316\|NC_000003.12:9388087_9390497\_-       Novel_circRNA   Intergenic          4.86113657       0.47990746     −3.340465522             1.27×10^−3^   Down
  circRNA_09849\|NC_000005.10:155854549_155870424\_+   Novel_circRNA   Intergenic          10.1352809       3.446893745    −1.556017338             1.29×10^−3^   Down
  circRNA_11131\|NC_000006.12:130175841_130184623\_-   SAMD3           Sense-overlapping   14.8131577       6.226198349    −1.25045577              2.38×10^−3^   Down
  circRNA_15991\|NC_000010.11:67988663_68014186\_-     HERC4           Sense-overlapping   8.52545734       3.069284144    −1.473875016             3.67×10^−3^   Down
  circRNA_24400\|NC_000017.11:64052780_64053371\_-     ERN1            Sense-overlapping   4.25072746       0.333416255    −3.672313416             4.69×10^−3^   Down
  circRNA_12107\|NC_000007.14:73225711_73226051\_+     Novel_circRNA   Intergenic          4.18052411       0.328072145    −3.671598812             6.84×10^−3^   Down

Comparison A (Group a vs. Group control), B (Group b vs. Group control) and C (Group c vs. Group control). Groups: a, QSBSS patients with coronary heart disease (n=5); b, QSBSS patients with chronic gastritis (n=5); c, QSBSS patients with rheumatoid arthritis (n=5). circRNA, circular RNA; QSBSS, Qi stagnation and blood stasis syndrome; BM, base mean.

###### 

Detailed information of the top 10 upregulated and 10 downregulated mRNAs.

  A, Group a                                                                                                                            
  ---------------- --------------- ---------------------------- ---------------- -------------- ------------------------ -------------- ----------------
                                                                                                                                        
  XM_011510258.1   LOC100996763    Chr 1:148595857-148712520    128.7757693      709.5584027    2.462060276              1.33×10^−8^    Up
  XM_011527030.1   PLAUR           Chr 19:43646095-43670547     20.98685367      159.9897378    2.930421569              1.43×10^−8^    Up
  NM_014779.3      TSC22D2         Chr 3:150408335-150466431    32.78009306      192.5260299    2.554161659              3.34×10^−7^    Up
  XM_011533056.1   SLC8A1          Chr 2:40097270-40611053      0.531373673      34.14398459    6.005760869              5.52×10^−7^    Up
  XM_011539511.1   RAB11FIP2       Chr 10:118004916-118046603   10.20389314      82.18530749    3.009760806              6.06×10^−7^    Up
  NM_001190794.1   NCF2            Chr 1:183555563-183590876    486.8308955      1954.560939    2.005351932              7.19×10^−7^    Up
  XM_011541247.1   AMPD2           Chr 1:109616104-109632051    155.6506686      651.8712724    2.066275324              1.11×10^−6^    Up
  NM_145197.2      LIPT1           Chr 2:99154955-99163157      1.075086932      30.27521872    4.815612156              1.43×10^−6^    Up
  XM_011547051.1   LILRB2          Chr 19:54273821-54281184     0.503235941      46.09541145    6.517244373              1.68×10^−6^    Up
  XM_011515764.1   DBF4            Chr 7:87876216-87909541      4.68292893       47.08883617    3.329902018              4.28×10^−6^    Up
  XM_005271698.1   MSANTD4         Chr 11:105995623-106022403   194.4517168      20.76045887    −3.227501735             2.96×10^−10^   Down
  XM_006714859.2   GRK6            Chr 5:177403204-177442901    1476.118081      321.2056531    −2.200238944             6.66×10^−8^    Down
  XM_011523632.1   SMYD4           Chr 17:1779485-1830634       73.7875596       6.195994556    −3.57396982              1.05×10^−7^    Down
  NM_001242851.1   RNF146          Chr 6:127266610-127288567    371.8379549      80.23879516    −2.212302191             4.86×10^−7^    Down
  NM_001032373.1   ZNF226          Chr 19:44165073-44178381     170.6048738      26.99739109    −2.659766959             5.40×10^−7^    Down
  NM_001243775.1   LIMA1           Chr 12:50175788-50283546     41.82845265      2.271853512    −4.202542911             8.07×10^−7^    Down
  XM_006717434.2   KIN             Chr 10:7750962-7787981       82.05054397      7.772315863    −3.400096461             9.81×10^−7^    Down
  NM_001286646.1   SLC45A4         Chr 8:141207166-141308305    338.7563764      79.07800005    −2.098899813             2.32×10^−6^    Down
  NM_002250.2      KCNN4           Chr 19:43766533-43781257     148.593054       28.77836175    −2.368310307             3.38×10^−6^    Down
  NM_001698.2      AUH             Chr 9:91213815-91361913      28.1687429       1.14588383     −4.619562486             4.59×10^−6^    Down
                                                                                                                                        
  **B, group b**                                                                                                                        
                                                                                                                                        
  **Gene ID**      **Gene name**   **Gene location**            **BM_control**   **BM_QSBSS**   **log2 (fold change)**   **P-value**    **Regulation**
                                                                                                                                        
  NM_001291963.1   DAP             Chr 5:10679230-10761272      3.083042965      75.88918508    4.621467403              1.23×10^−9^    Up
  XM_005274953.3   HLA-DQA1        Chr 6:32628179-32647062      0.167025521      213.6609304    10.32103885              4.22×10^−7^    Up
  NM_001098272.2   HMGCS1          Chr 5:43289395-43313512      2.515427217      41.20482768    4.033938026              1.18×10^−6^    Up
  NM_173214.2      NFAT5           Chr 16:69565094-69704666     137.1028468      614.3398191    2.163778369              2.45×10^−6^    Up
  XM_005271523.3   ZBTB44          Chr 11:130226677-130314686   45.08295693      256.2092972    2.50666878               6.35×10^−6^    Up
  NM_001282441.1   GNA12           Chr 7:2728112-2844324        0.341979162      20.09576134    5.876839008              7.94×10^−6^    Up
  NM_014779.3      TSC22D2         Chr 3:150408335-150466431    31.77170716      167.9742018    2.402425158              1.05×10^−5^    Up
  XM_011514978.1   ABCC10          Chr 6:43427366-43450430      1.615876704      29.14153126    4.172687661              1.32×10^−5^    Up
  XM_006717383.2   CREM            Chr 10:35126791-35212958     2.740860538      32.21154032    3.554876823              2.26×10^−5^    Up
  XM_011521157.1   DENND4A         Chr 15:65658046-65792293     1.968440767      30.31479595    3.944896906              2.29×10^−5^    Up
  NM_003037.3      SLAMF1          Chr 1:160608100-160647295    42.62133994      0.782999144    −5.766421409             1.49×10^−8^    Down
  NM_153373.3      PHYKPL          Chr 5:178208497-178232791    58.97775271      2.014078279    −4.87197919              4.93×10^−8^    Down
  XM_005262404.3   HTATSF1         Chr X:136497079-136512346    51.81171726      3.116477327    −4.055290279             1.14×10^−7^    Down
  NM_001099696.2   REPIN1          Chr 7:150368189-150374044    258.5384205      43.226086      −2.580404575             4.48×10^−7^    Down
  XM_011512333.1   STAG1           Chr 3:136336233-136752403    27.59010032      0.596392567    −5.531744615             1.06×10^−6^    Down
  XM_006713188.2   SHISA5          Chr 3:48467798-48504826      587.4466021      123.8085754    −2.246346475             1.24×10^−6^    Down
  XM_011519861.1   C11orf58        Chr 11:16613132-16756881     668.0596614      132.9186866    −2.329433007             1.96×10^−6^    Down
  XM_011523594.1   TBCD            Chr 17:82752064-82945922     39.27908367      1.676943758    −4.549855064             2.95×10^−6^    Down
  XM_005252018.1   ODF2            Chr 9:128455186-128501292    31.19036594      0.990939876    −4.976159143             3.52×10^−6^    Down
  XM_006714696.2   CAST            Chr 5:96525267-96779595      33.84494268      1.942626191    −4.122860051             4.68×10^−6^    Down
                                                                                                                                        
  **C, group c**                                                                                                                        
                                                                                                                                        
  **Gene ID**      **Gene name**   **Gene location**            **BM_control**   **BM_QSBSS**   **log2 (fold change)**   **P-value**    **Regulation**
                                                                                                                                        
  XM_011534376.1   SCFD2           Chr 4:52872982-53366075      1.559496265      69.36997091    5.475159277              5.61×10^−9^    Up
  XM_005259105.1   GRAMD1A         Chr 19:34994784-35026471     2.850311301      99.56136105    5.126394554              1.23×10^−7^    Up
  XM_011515624.1   PHF14           Chr 7:10973872-11169630      0.979140157      33.97667549    5.1168855                2.58×10^−7^    Up
  XM_011547517.1   FCAR            Chr 19:54874248-54890472     6.35636695       66.26373583    3.381945224              3.46×10^−7^    Up
  XM_011529325.1   SIGLEC1         Chr 20:3686970-3707128       5.397654189      124.1005265    4.523032875              9.33×10^−7^    Up
  NM_001276286.1   BBX             Chr 3:107522936-107811324    53.75421935      316.8543227    2.559369792              1.05×10^−6^    Up
  XM_006722540.2   TCF4            Chr 18:55222331-55664787     0.55892364       25.69005846    5.522415166              2.04×10^−6^    Up
  NM_014779.3      TSC22D2         Chr 3: 150408335-150466431   33.32937132      172.858216     2.374723167              3.63×10^−6^    Up
  XM_011511806.1   IL1R2           Chr 2:101991844-102028544    11.97084228      84.73814635    2.823486905              5.41×10^−6^    Up
  XM_011537996.1   GRASP           Chr 12:52006940-52015889     13.22125101      90.58703153    2.776445835              7.61×10^−6^    Up
  NM_184234.2      RBM39           Chr 20:35701347-35742312     311.6823768      25.6690681     −3.601973759             1.00×10^−12^   Down
  XM_006711370.2   UCHL5           Chr 1:193012250-193060080    75.60834192      0.585379421    −7.013029579             1.78×10^−11^   Down
  NM_001177676.1   GPR68           Chr 14:91232532-91253925     144.6164402      13.2274947     −3.450619823             9.93×10^−10^   Down
  NM_001242599.1   RBM39           Chr 20:35701347-35742312     63.54456584      3.153938054    −4.332542525             5.76×10^−9^    Down
  XM_005259103.2   GRAMD1A         Chr 19:34994784-35026471     582.9135127      103.4609801    −2.494195081             3.41×10^−8^    Down
  NM_021983.4      HLA-DRB4        Chr 1:32542598-32557561      1126.115406      223.72947      −2.331527476             1.62×10^−7^    Down
  NM_001162953.2   SYTL2           Chr 11:85694224-85811159     231.7902901      40.56415454    −2.514542807             2.95×10^−7^    Down
  NM_001287340.1   NADK2           Chr 5:36192592-36242279      179.4003614      31.63501319    −2.503588694             1.02×10^−6^    Down
  XM_011547738.1   LOC105369230    Chr 1:32723350-32757450      4437.862978      689.6928005    −2.685839312             1.07×10^−6^    Down
  XM_005266520.2   ZMYM2           Chr 13:19958670-20091829     207.5631578      40.26949202    −2.365791212             1.76×10^−6^    Down

Comparison A (Group a vs. Group control), B (Group b vs. Group control) and C (Group c vs. Group control). Groups: a, QSBSS patients with coronary heart disease (n=5); b, QSBSS patients with chronic gastritis (n=5); c, QSBSS patients with rheumatoid arthritis (n=5). QSBSS, Qi stagnation and blood stasis syndrome; Chr, chromosome; BM, base mean.
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